Prime Medicine is a gene editing biotechnology company.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/13/2021 | Series B | $200MM | $xx.xx | $1.23B | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
45,658,957
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price
|
||||||
10/15/2020 | Series A | $115.76MM | $xx.xx | $231.52MM | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners | |
Price per Share
$xx.xx
Shares Outstanding
115,761,842
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners
|